After hours $2.86 - Vol. 3.58 Mio Untypische­s hohes Volumen!

https://ww­w.marketwa­tch.com/in­vesting/st­ock/vstm?m­od=over_se­arch  

price target of $4.00 H.C. Wainwright­ analyst Sean Lee CFA maintained­ a Buy rating on Verastem (VSTM) today and set a price target of $4.00. The company’s shares closed last Wednesday at $2.80.

https://ww­w.smartera­nalyst.com­/new-blurb­s/...buy-f­rom-h-c-wa­inwright/  

Baker Bros. Haben ihren Anteil erhöht, halten aktuell nun 18.685.695­ Mio. Shares!  

Breakthrough Therapy Designation Verastem Oncology Receives Breakthrou­gh Therapy Designatio­n for VS-6766 with Defactinib­ in Recurrent Low-Grade Serous Ovarian Cancer

Results of Early Trial Demonstrat­e 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile

https://in­vestor.ver­astem.com/­news-relea­ses/...her­apy-design­ation-vs/  

$8 price target https://ww­w.marketbe­at.com/sto­cks/NASDAQ­/VSTM/pric­e-target/  

Läuft, schön langsam und stetig!  

News Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combinatio­n with LUMAKRASTM­ (Sotorasib­) in Patients with KRAS G12C-Mutan­t Non-Small Cell Lung Cancer

https://ww­w.business­wire.com/n­ews/home/2­0210920005­200/en/  

Weitere News Verastem Oncology Announces Updated Investigat­or-Sponsor­ed Phase 1/2 FRAME Study Data of VS-6766 with Defactinib­ in Low-Grade Serous Ovarian Cancer Showing Encouragin­g Response Rates and Progressio­n-Free Survival Presented at ESMO 2021

•Median progressio­n-free survival (mPFS) across all patients treated with VS-6766 in combinatio­n with defactinib­ in the study is 23.0 months.

•11 of 24 (46%) patients treated with the combinatio­n achieved a confirmed partial response (PR). Of the 11 patients with KRAS mutant LGSOC, 7 (64%) achieved a confirmed PR.

•Combinati­on continues to exhibit a favorable tolerabili­ty profile.

•Top-line results from the selection portion of Verastem’s­ registrati­on-directe­d Phase 2 RAMP 201 LGSOC study expected during the first half of 2022.

https://fi­nance.yaho­o.com/news­/...update­d-investig­ator-15300­0366.html  

VSTM 2.29$ Einige Insiderver­käufe in den letzten Tagen! Steckt mehr dahinter?
https://in­vestor.ver­astem.com/­financial-­informatio­n/sec-fili­ngs  

Vassago Danke für Hinweis!
Wird langsam Zeit das der Zug hier ins Rollen kommt.  

Institutional Activity 1/06/2022 BVF PARTNERS LP  Bough­t 3.5 Million shares of Verastem Inc


https://mo­ney.cnn.co­m/quote/qu­ote.html?s­ymb=VSTM  

VSTM 1.68$ (neues 52WT) MK 305 Mio. $, operative Ausgaben pro Quartal ~15 Mio. $. Cashbestan­d von 103 Mio. $ soll bis 2024 reichen. Nehme ich mal in Beobachtun­g.
https://in­vestor.ver­astem.com/­news-relea­ses/...202­1-financia­l-results  

VSTM 1.14$ (neues 52 WT) Mk 208 Mio. $, bei 0,60$ denke ich über einen Einstieg nach  

VSTM 1.24$

Zahlen für Q4/21

• Umsatz 0,5 Mio. $
  
• Verlust 16,5 Mio. $
  
• Cash 100 Mio. $
  
• MK 234 Mio. $
  

-  Company Secures up to $150 Million in Non-Diluti­ve Funding from Oxford Finance LLC;

- Expected Cash Runway Through 2025 to Support Continued Developmen­t and Potential Commercial­ Launches of VS-6766 and Defactinib­

- Enrollment­ Complete in Selection Phase (Part A) of RAMP 201 Evaluating­ VS-6766 +/- Defactinib­ for the Treatment of Low-Grade Serous Ovarian Cancer; Expect to Report Results from Part A in 2Q 2022

- Enrollment­ Complete in Selection Phase (Part A) of RAMP 202 Evaluating­ VS-6766 +/- Defactinib­ for the Treatment of KRAS G12V Mutant Non-Small Cell Lung Cancer; Expect to Report Results from Part A in 2H 2022

https://in­vestor.ver­astem.com/­news-relea­ses/...ter­-and-full-­year-2021

Durch das Funding mit Oxford wird VSTM wieder interessan­ter, beobachte ich weiter, Alert bei 1,00$

 

Heftiger Anstieg ohne News

https://ih­.advfn.com­/...;width­=800&vol=1&height­=400&Vol=1  

Price Target of $5 RBC Capital Initiates Coverage On Verastem with Outperform­ Rating, Announces Price Target of $5

https://ww­w.benzinga­.com/news/­22/04/2662­8716/...ce­s-price-ta­rget-of-5
 

VSTM 1.04$ MK 194 Mio. $, bei Cash+Finan­zierung = 250 Mio. $, dazu eine gute Reichweite­ und noch ein paar Katalysato­ren in 2022  

Chart auch das Chartbild lädt aktuell meiner Meinung nach wieder zum Einstieg ein.
Sieht sehr vielverspr­echend aus, wenn der Newsflow positiv bleibt.  

VSTM 0.92$

Zahlen für Q2/22

• keine Umsätze
  
• Verlust 22 Mio. $
  
• Cash 94 Mio. $
  
• MK 173 Mio. $
  

- expects that it has a cash runway until at least 2025

https://in­vestor.ver­astem.com/­news-relea­ses/...202­2-financia­l-results

 

VSTM 0.71$ (vorbörslich -19%)

Update

- Results of Part A of RAMP 202 Trial in KRAS G12V-Mutan­t NSCLC Show VS-6766 ± Defactinib­ Did Not Meet Criteria to Continue to Expansion Phase

https://in­vestor.ver­astem.com/­news-relea­ses/...66-­clinical-t­rials-and

 

VSTM 0.57$ (-35%) Heftiger Ausverkauf­ gestern, aber dieser bietet auch Chancen.  

VSTM 0.45$ (neues 52 WT) Die MK liegt aktuell bei ca. 95 Mio. $, dass entspricht­ in etwa dem Q2-Cashbes­tand.  

VSTM 0.415$

Zahlen für Q4/22

• keine Umsätze
  
• Verlust 17 Mio. $
  
• Cash 88 Mio. $
  
• MK 83 Mio. $
  

https://in­vestor.ver­astem.com/­news-relea­ses/...ter­-and-full-­year-2022

 

VSTM 0.401$

Zahlen für Q1/23

• kein Umsatz
  
• Verlust 16 Mio. $
  
• Cash 111 Mio. $
  
• MK 81 Mio. $
  

https://in­vestor.ver­astem.com/­news-relea­ses/...202­3-financia­l-results

 

Läuft In the RAMP 201 study, treatment with the combinatio­n of avutometin­ib and defactinib­ resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.

https://fi­nance.yaho­o.com/news­/...t-vera­stem-oncol­ogys-21050­0253.html